Actonel (risedronate) for osteoporosis

The FDA has now approved Actonel (risedronate) for osteoporosis. The HPB is considering this new indication for Canada.

Actonel is a bisphosphonate...similar to Fosamax (alendronate). But until now, Actonel was approved only for Paget's disease.

The new U.S. indication is to prevent or treat osteoporosis in postmenopausal women...or in patients taking glucocorticoids.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote